Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Not one, but two positive news items out today

<< Previous

Bullboard Posts

Next >>

Comment by ONCInvestoron Oct 24, 2023 2:13pm

163 Views

Post# 35698657

RE:RE:RE:RE:RE:RE:RE:RE:Not one, but two positive news items out today

This is a good post by Quentin. And a good reminder of the long, long history of this company. I had actually forgotten about the proposed bladder trial. If memory serves, that came out of nowhere after the failure of the head-and-neck trial. I should have bailed after that trial, but FOMO kept me in it. Classic investor behavioural error.

I very much hope that we coming to the end of the road with this company.

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China